Pages that link to "Q36697501"

The following pages link to Retigabine (Q36697501):

Displaying 36 items.

• New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels (Q24654230) (← links)
• Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions (Q28245021) (← links)
• A swell in the armamentarium of antiepileptic drug targets (Q30429603) (← links)
• Potassium dynamics in the epileptic cortex: new insights on an old topic (Q33788071) (← links)
• Emerging drugs for epilepsy (Q34688725) (← links)
• Effect of the new antiepileptic drug retigabine in a rodent model of mania (Q34726613) (← links)
• Pharmacological management of epilepsy: recent advances and future prospects (Q34823174) (← links)
• Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. (Q35683922) (← links)
• Clinical utility of adjunctive retigabine in partial onset seizures in adults. (Q35717049) (← links)
• Atomic basis for therapeutic activation of neuronal potassium channels (Q36033788) (← links)
• The Sensorless Pore Module of Voltage-gated K Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine (Q36548403) (← links)
• The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential. (Q36675813) (← links)
• K channel modulators for the treatment of neurological disorders and autoimmune diseases (Q37162392) (← links)
• Voltage-gated potassium channels as therapeutic targets (Q37464784) (← links)
• The contribution of Kv7 channels to pregnant mouse and human myometrial contractility (Q37580235) (← links)
• New and investigational antiepileptic drugs (Q37638688) (← links)
• Drug interactions involving the new second- and third-generation antiepileptic drugs (Q37658910) (← links)
• Emerging drugs for partial onset seizures. (Q37754477) (← links)
• Novel medications for epilepsy (Q37950518) (← links)
• The mechanism of action of retigabine (ezogabine), a first‐in‐class K channel opener for the treatment of epilepsy (Q37973378) (← links)
• Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate (Q37992162) (← links)
• Potassium channels: a review of broadening therapeutic possibilities for neurological diseases (Q38059092) (← links)
• Desensitization of chemical activation by auxiliary subunits: convergence of molecular determinants critical for augmenting KCNQ1 potassium channels (Q41988367) (← links)
• Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians (Q42385228) (← links)
• Bimodal effects of the Kv7 channel activator retigabine on vascular K currents (Q42424886) (← links)
• Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter (Q42972474) (← links)
• Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats (Q43848769) (← links)
• Expression and function of K(v)7 channels in murine myometrium throughout oestrous cycle. (Q44669252) (← links)
• Inhibition by an excitatory conductance: a paradox explained. (Q46035841) (← links)
• Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. (Q46387953) (← links)
• Somatostatin receptor subtype 4 couples to the M-current to regulate seizures. (Q46667158) (← links)
• A pharmaco-EEG study of the interaction between ethanol and retigabine in rabbits. (Q48335756) (← links)
• Antiepileptic drugs in development pipeline: A recent update (Q49882750) (← links)
• Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy (Q53166134) (← links)
• Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips. (Q53193958) (← links)
• Copper mediated C-H amination with oximes: en route to primary anilines. (Q55562302) (← links)